Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2004-04-18
2010-12-21
Steadman, David J (Department: 1656)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C424S094610
Reexamination Certificate
active
07855063
ABSTRACT:
A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule. A glucocerebrosidase preparation comprising a population of glucocerebrosidase molecules, wherein substantially each of said glucocerebrosidase molecules: (i) has an amino acid sequence at least 95 percent homologous to an amino acid sequence set forth by SEQ ID NO: 1 or 8; (ii) is glycosylated at, or has an aspartatic acid residue at, glycosylation residue 1 of said amino acid sequence; and (iii) is independently unglycosylated at one or more glycosylation residues selected from the group consisting of glycosylation residues 2, 3 and 4 of said amino acid sequence.
REFERENCES:
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5879680 (1999-03-01), Ginns et al.
patent: 7442537 (2008-10-01), Benson et al.
patent: 2007/0038380 (2007-02-01), Somers et al.
patent: WO 01/77307 (2001-10-01), None
patent: WO 2004/091475 (2004-10-01), None
Dvir et al., “X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease”, EMBO Reports 4:704-709, 2003.
Branden et al., “Introduction to Protein Structure Second Edition”, Garland Publishing Inc., New York, 1999, pp. 374-375.
Drenth et al., “Principles of X-ray Crystallography,” Springer, New York, 1999, p. 1.
Kierzek et al., “Models of protein crystal growth”, Biophys Chem 91:1-20, 2001.
Wiencek, “New Strategies for Protein Crystal Growth”, Ann Rev Biomed Eng 1:505-534, 1999.
Buts et al.,“Impact of natural variation in bacterial F17G adhesins on crystallization behaviour”, Acta Cryst D61:1149-1159, 2005.
Skarzynski et al., “Industrial perspective on X-ray data collection and analysis”, Acta Cryst D62:102-107, 2006.
Kundrot et al., “Which strategy for a protein crystallization project?”, Cell. Mol. Life Sci. 2004, 61: 525-536.
Weber, “Overview of Protein Crystallization Methods”, Methods in Enzymology, 1997, vol. 276, pp. 13-22.
Cudney, “Protein Crytallization and Dumb Luck”, Rigaku Journal, 1999, vol. 16, No. 1, pp. 1-7.
Cudney, “Protein Crytallization and Dumb Luck”, Rigaku Journal, 1999, vol. 16, No. 1, pp. 1-7.
McPherson et al., “Current approaches to macromolecular crytallization”, Eur. J. Biochem. 189:1-23, 1990.
Tonetti et al., Acta Crystallogr D Biol Crystallogr 54:684-687, Jul. 1998.
Hogg et al., Acta Cryst. (2002). D58, 1734-1739, 2002.
Kalisz et al., J. Mol. Biol. 213:207, 209, 1990.
Tayebi et al., Mol. Genet. Metabol. 79:104-109, 2003.
Grueninger-Leitch et al., Protein Science 5:2617-2622, 1996.
Mills et al., Tetrahedron: Asymmetry 11:75-93, 2000.
Blundell et al. “High-Throughput Crystallography for Lead Discovery in Drug Design”, Nature Reviews: Drug Disvocery, 1(1): 45-54, 2002.
Brumshtein et al. “Structural Comparison of Differently Glycosylated Forms of Acid-β-Glucosidase, the Defective Enzyme in Gaucher Disease”, Acta Crystallographica, Section D, Biological Crystallography, 62(Pt.12): 1458-1465, 2006.
Grabowski et al. “Enzyme Therapy for Gaucher Disease: The First 5 Years”, Blood Reviews, 12(2): 115-133, 1998. p.118-119, 121-123, 127-131.
Rayon et al. “The Protein N-Glycosylation in Plants”, Journal of Experimental Botany, 49(326): 1463-1472, 1998.
Zhao et al. “Gaucher Disease: Perspectives on A Prototype Lysosomal Disease”, Cellular and Molecular Life Sciences, CMLS, 59(4): 694-707, 2002. Table 1, p. 698, 702, 704.
Grabowski et al. “Human Acid β-Glucosidase—Use of Conduritol B Epoxide Derivatives to Investigate the Catalytically Active Normal and Gaucher Disease Enzymes”, The Journal of Biological Chemistry,261 (18): 8263-8269, 1986.
Berg-Fussman et al. “Human Acid β-Glucosidase—N. Glycosylation Site Occupancy and the Effect of Glycosylation on Enzymatic Activity”, The Journal of Biological Chemistry, 268(20):14861-14866, 1993.
Roeber et al. “Crystallization and Preliminary X-Ray Analysis of Recombinant Human Acid Beta-Glucocerbrosidase, A Treatment for Gaucher's Disease”, Biological Crystallography, D59: 343-344, 2003.
Sawkar et al. “Chemical Chaperones Increase the Cellular Activity of N370S β-Glucosidase:, A Therapeutic Strategy for Gaucher Disease”, PNAS, 99(24): 15428-15433, 2002.
Erickson et al. “Biosynthesis of the Ltsomal Enzyme Glucocerebrosidase”, The Journal of Biological Chemistry, 260(26): 14319-14324, 1985.
Ahn et al. “Crystal Structure of Saposin B Reveals A Dimeric Shell for Lipid Binding”, Proc. Natl. Acad. Sci. USA, 100(1): 38-43, 2003.
Amaral et al. “Gaucher Disease: Expression and Characterization of Mild and Severe Acid β-Glucosidase Mutations in Portuguese Type 1 Patients”, European Journal of Human Genetics, 8: 95-102, 2000.
Amaral et al. “Type 1 Gaucher Disease: Identification of N396T and Prevalence of Glucocerebrosidase Mutations in the Portuguese”, Human Mutation, 8: 280-281, 1996.
Beutler “Economic Malpractice in the Treatment of Gaucher's Disease”, The American Journal of Medicine, 97: 1-2, 1994.
Beutler et al. “Gaucher Disease”, The Metabolic and Molecular Bases of Inherited Disease, Chap.146: 3635-3668, 2001.
Beutler et al. “Two New Gaucher Disease Mutations”, Human Genetics, 93: 209-210, 1994.
Brünger et al. “Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination”, Acta Crystallographica Section D, 54: 905-921, 1998.
Buccoliero et al. “The Role of Sphingolipids in Neural Development: Lessons From Models of Sphingolipid Storage Diseases”, Neurochemical Research, 27(7/8): 565-574, 2002.
Charrow et al. “The Gaucher Registry. Demographics and Disease Characteristics of 1698 Patients With Gaucher Disease”, Archive of Internal Medicine, 160: 2835-2843, 2000.
Chi et al. “Crystal Structure of the β-Glycosidase From the Hyperthermophile Thermosphaera Aggregans: Insights Into Its Activity and Thermostability”, FEBS Letters, 445: 375-383, 1999.
Cox et al. “Novel Oral Treatment of Gaucher's Disease With N-Butyldeoxynojirimycin (OGT 918) to Decrease Substrate Biosynthesis”, The Lancet, 355: 1481-1485, 2000.
Davies et al. “Structures and Mechanisms of Glycosyl Hydrolases”, Structure, 3: 853-859, 1995.
Dinur et al. “Human Acid β-Glucosidase: Isolation and Amino Acid Sequence of A Peptide Containing the Catalytic Site”, Proc. Natl. Acad. Sci. USA, 83: 1660-1664, 1986.
Fabrega et al. “Human Glucocerebrosidase: Heterologous Expression of Active Site Mutants in Murine Null Cells”, Glycobiology, 10(11): 1217-1224, 2000.
Fan “A Contradictory Treatment for Lysosomal Storage Disorders: Inhibitors Enhance Mutant Enzyme Acitivity”, Trends in Pharmacological Sciences, 24(7): 355-360, 2003.
De La Fortelle et al. “Maximum-Likelihood Heavy-Atom Parameter Refinement for Multiple Isomorphous Replacement and Multi
Dvir Hay
Futerman Anthony
Harel Michal
Silman Israel
Sussman Joel L.
Steadman David J
Yeda Research And Development Co. Ltd.
LandOfFree
Partially deglycosylated glucocerebrosidase polypeptide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Partially deglycosylated glucocerebrosidase polypeptide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partially deglycosylated glucocerebrosidase polypeptide and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168840